Skip to content
HomeLatest newsStatement on the release of the Janssen U.S. Transparency Report
Beerse Scientists

Statement on the release of the Janssen U.S. Transparency Report

Below, please find a statement on the Janssen U.S. Transparency Report from Joaquin Duato, Johnson & Johnson Executive Vice President and Worldwide Chairman, Pharmaceuticals. You can view the full report on Janssen.com.

“We are pleased to release the inaugural Janssen U.S. Transparency Report, in which we are disclosing more information about our business practices, including those related to pricing. This report builds on our history of responsible pricing practices and our ongoing efforts to provide more transparency into how we operate. These disclosures are steps that we can take as one company as we continue to work with others in the health care system to address stakeholder concerns about U.S. health care costs.” - Joaquin Duato, Executive Vice President and Worldwide Chairman, Pharmaceuticals

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.